Back to results
US 2007/0161065 A1Published application
DIAGNOSIS, PREVENTION AND TREATMENT OF CROHN'S DISEASE USING THE OmpC ANTIGEN
AssigneesCedars-Sinai Medical Center, The Regents of the University of California
InventorsStephan Targan, Jonathan Braun, Christopher Sutton
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of diagnosing Crohn's disease in a subject by determining the presence or absence or IgA anti-OmpC antibodies in the subject, where the presence of the IgA anti-OmpC antibodies indicates that the subject has Crohn's disease.
Claims16
A diagnostic assay, said diagnostic assay comprising:
- determining the presence or absence of IgA anti-outer membrane protein C (anti-OmpC) antibodies in a sample, wherein the presence of said IgA anti-OmpC antibodies is associated with Crohn's disease.
A diagnostic assay, said diagnostic assay comprising:
- (a) obtaining a sample from a subject suspected of having inflammatory bowel disease;
- (b) contacting the sample with an OmpC antigen, or reactive fragment thereof, under conditions suitable to form a complex of the OmpC antigen, or reactive fragment thereof, and IgA anti-OmpC antibody;
- (c) contacting said complex with a labeled anti-IgA antibody to form a labeled complex;
- and
- (d) detecting the presence or absence of said labeled complex, thereby determining the presence or absence of IgA anti-OmpC antibodies,
- associating the presence of said IgA anti-OmpC antibodies in said sample with Crohn's disease.
3 more elements
A diagnostic assay, said diagnostic assay comprising:
- (a) contacting a sample from a subject suspected of having inflammatory bowel disease with an OmpC antigen, or reactive fragment thereof, under conditions suitable to form a complex of the OmpC antigen, or reactive fragment thereof, and IgA anti-OmpC antibody, wherein said OmpC antigen comprises the amino acid sequence of SEQ ID NO:
- 1;
- (b) contacting said complex with a labeled anti-IgA antibody to form a labeled complex;
- (c) detecting the presence or absence of said labeled complex, thereby determining the presence or absence of IgA anti-OmpC antibodies;
- and associating the presence of said IgA anti-OmpC antibodies in said sample with Crohn's disease.
2 more elements
A diagnostic assay, said diagnostic assay comprising:
- determining the presence or absence of IgA anti-OmpC antibodies in a sample, where the presence of said IgA anti-OmpC antibodies in said sample is associated with Crohn's disease.
An assay method, said assay method comprising:
- determining the presence or absence of IgA anti-OmpC antibodies and the presence or absence of IgA ASCA in a sample, wherein the presence of said IgA anti-OmpC antibodies and the presence of said IgA ASCA are each independently associated with Crohn's disease.
An assay method, said assay method comprising:
- (a) obtaining a sample from a subject suspected of having inflammatory bowel disease;
- (b) contacting a portion of the sample with an OmpC antigen, or reactive fragment thereof, under conditions suitable to form a complex of the OmpC antigen, or reactive fragment thereof, and IgA anti-OmpC antibody;
- (c) contacting said complex from step (b) with a labeled anti-IgA antibody to form a labeled complex;
- (d) detecting the presence or absence of said labeled complex from step
- (c), thereby determining the presence or absence of IgA anti-OmpC antibodies,
- (e) contacting another portion of the sample with one or more antigens specific for IgA ASCA under conditions suitable to form a complex of the one or more antigens specific for ASCA and IgA ASCA;
- (f) contacting said complex from step (e) with a labeled anti-IgA antibody to form a labeled complex;
- and
- (g) detecting the presence or absence of said labeled complex from step (f), thereby determining the presence or absence of ASCA, where the presence of said IgA anti-OmpC antibodies and the presence of ASCA in said sample are each independently associated with Crohn's disease.
6 more elements
An assay method, said assay method comprising:
- determining the presence or absence of IgA anti-OmpC antibodies, IgA ASCA, IgA anti I-2 polypeptide antibodies and peri-nuclear anti-neutrophil antibodies (pANCA) in a sample, where the presence of said IgA anti-OmpC antibodies, IgA ASCA, IgA anti I-2 polypeptide antibodies and peri-nuclear anti-neutrophil antibodies (pANCA) in said sample associates said sample with Crohn's disease.
Dependencies are inferred from the claim text.